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C O R R E S P O N D E N C E
Vancomycin Minimum Inhibitory 
Concentration Is 
Not a Substitute for Clinical 
Judgment: Response to 
Healthcare-Associated 
Ventriculitis and Meningitis 
To the Editor—We read with inter-est 
the new clinical practice guideline for 
healthcare-associated ventriculitis and 
meningitis published in Clinical Infectious 
Diseases [1]. The guideline recommends 
consideration of alterna-tive therapies for 
the treatment of me-thicillin-resistant 
Staphylococcus aureus (MRSA) meningitis 
and ventriculitis for isolates with a 
vancomycin minimum in-hibitory 
concentration (MIC)  ≥1μg/mL. We believe 
this recommendation places inappropriate 
emphasis on a single deter-minant of 
antimicrobial therapy that has uncertain 
clinical relevance and variable 
accuracy depending on the antimicro-
bial susceptibility testing (AST) method 
used. This may lead clinicians to use less 
well-evidenced strategies in cases likely 
to respond to vancomycin.
AST can be performed by any of sev-
eral methods, including broth microdi-
lution (BMD), gradient diffusion (Etest), 
disc diffusion, and automated systems 
[2]. Several investigators have found 
that Etest methods consistently yield 
higher MICs than reference BMD [3–6]. 
Automated systems, used by most clin-
ical laboratories, also vary in vancomy-
cin MIC results, with VITEK 2 systems 
yielding lower MICs and Microscan 
systems higher MICs than reference 
BMD [4, 6]. Reports are conflicting for 
Phoenix systems [4, 6]. Therefore, a 
recommendation to change therapy on 
the basis of MIC testing alone leaves 
much in question, because the MIC 
result varies based on the method used. 
Furthermore, because clinicians are not 
frequently able to influence the type of 
testing available at their site, there is a 
risk of drug selection becoming more 
a function of laboratory testing than of 
clinical judgment.
The threshold MIC recommended for 
consideration of alternative therapies 
by Tunkel and colleagues [1] in the new 
guideline, ≥1  μg/mL, is more conserv-
ative than any previous guideline; the 
vancomycin monitoring guideline [7] 
advocated that therapy change be consid-
ered only with an MIC ≥2 μg/mL, and the 
more recent MRSA infection guideline 
[8] recommended change when the MIC
indicates nonsusceptibility (>2  μg/mL)
or in cases of clinical failure. Presumably,
the new guideline for meningitis and ven-
triculitis advocates a lower MIC threshold 
owing to lower achievable vancomycin
concentrations in the cerebrospinal fluid.
Prior evidence predicts achievement of
the pharmacodynamic target for vanco-
mycin, an area under the curve (AUC)/
MIC ratio of  ≥400, for isolates with
an MIC  ≤1  μg/mL, when vancomycin
troughs of 15–20 mg/L are maintained for 
a patient of average weight and normal
renal function [7]. This AUC/MIC target 
represents our best correlate of vanco-
mycin clinical success in treating lower 
respiratory tract infections [9], but its 
application to meningitis and ventriculi-
tis is unknown. There are conflicting data 
on the association of clinical failures with 
high but susceptible vancomycin MICs 
[10]; no specific studies for central nerv-
ous system infections are available.
We agree with the authors that noso-
comial MRSA meningitis and ventricu-
litis are commonly encountered clinical 
situations for which few high-quality 
clinical studies are available; we look 
forward to more data to clarify the role 
of newer agents. We contend that AST 
is one of several important considera-
tions in determining optimal therapy for 
MRSA infections, but as a sole criterion 
it glosses over considerable nuance and 
uncertainty in the evidence. Therefore, 
we suggest that the patient’s clinical con-
dition, response to initial therapy, and 
laboratory AST method should be con-
sidered along with the MIC to assess the 
appropriateness of an alternative therapy.
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